Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG4 vs 20vPnC in Healthy Infants
NCT07629440Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- May 2026
- Primary completion
- Jun 2029
- Countries
- 3
01
Overview
A Phase 3 trial of PG4 in pneumococcal disease, sponsored by Pfizer. Started May 2026; status: recruiting.
02
Drugs
PG4
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07629440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629440.